Pembrolizumab Salvage Add-On Therapy In Patients With Radioiodine-Refractory (Rair), Progressive Differentiated Thyroid Cancer (Dtc) Progressing On Lenvatinib: Results Of A Multicenter Phase Ii International Thyroid Oncology Group Trial

Annals of Oncology(2020)

引用 8|浏览41
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要